Funding for this research was provided by:
Pharmaceutical Research and Manufacturers of America Foundation (Informatics Fellowship)
National University of Singapore (NUS Development Grant)
American Cancer Society (Research Professorship)
National Human Genome Research Institute (R01 HG010040, U01 HG010961, U41 HG010972)
National Cancer Institute (R35 CA197568)
Article History
Received: 11 January 2022
Accepted: 16 August 2022
First Online: 26 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: H.L. is a consultant of Integrated DNA Technologies and on the SAB of Sentieon, Innozeen and BGI. M.M. is a consultant for Interline, Isabl, and Bayer; receives research support from Bayer, Janssen, and Ono; has a patent for <i>EGFR</i> mutations for lung cancer diagnosis issued, licensed, and with royalties paid from LabCorp and has issued patents and patents pending licensed to Bayer; and was a founding advisor of, consultant to, and equity holder in Foundation Medicine, shares of which were sold to Roche.